Position in ACLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$727,729
+$331,976 QoQ
Shares Held
6,338
+33.7% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACLX Over Time
Shares Held
Position Value (USD)
Derivatives in ACLX
reported options exposure · as of Sep 30, 2024CallValue
$0
CallShares
0
PutValue
$1,060,577
PutShares
12,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026GTS SECURITIES LLC holds $7,337,364 across 30 Biotechnology names. ACLX ranks #2 (9.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,738 | $776,086 | |
| 2 | ACLX |
Arcellx, Inc.
This page
|
6,338 | $727,729 | |
| 3 | APLS |
Apellis Pharmaceuticals, Inc.
|
15,604 | $627,748 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
767 | $592,614 | |
| 5 | CRSP |
CRISPR Therapeutics AG
|
7,787 | $370,427 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,052 | $348,075 | |
| 7 | INSM |
INSMED Inc
|
1,991 | $325,568 | |
| 8 | ABVX |
Abivax S.A.
|
2,652 | $295,300 |
All Filings in ACLX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $727,729 | 6,338 | Shares | Defined | 2026-05-15 | |
| 2024-09-30 | $395,753 | 4,739 | Shares | Defined | 2024-11-13 | |
| 2024-09-30 | $1,060,577 | 12,700 | Put | Defined | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||